0:000:00
<p>Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence. </p> <h2>Transcript</h2> <p class="MsoNormal"><strong><span style= "font-family: 'Calibri',sans-serif;">Dr. John Sweetenham:</span></strong> <span style= "font-family: 'Calibri',sans-serif;">Hello, I'm Dr. John Sweetenham, your host of the <em>ASCO Daily News</em> Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode. </span></p> <p class="MsoNormal"><span style= "font-family: 'Calibri',sans-serif;">Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating field...